Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma

Table 4

Summary of adjuvant and neoadjuvant studies: ongoing or unreported.

Trial	Design	Agent	Planned Accrual	Inclusion Criteria (stage/grade)	Inclusion Criteria (histology)
Adjuvant Trials
IMmotion010, (NCT03024996) [29]	Prospective, double-blinded, placebo controlled	Atezolizumab	664	Nonmetastatic	Clear cell, sarcomatoid
Checkmate-914, (NCT03138512) [22]	Prospective, double-blinded, placebo controlled	Nivolumab + Ipilimumab	800	pT2a – 4 N0 M0 (any), pT1-4 N1 M0 (any)	Clear cell
Keynote-564, (NCT03142334) [23]	Prospective, double-blinded, placebo controlled	Pembrolizumab	950	pT2 N0 M0 (grade 4 or sarcomatoid), pT3-4 N0 M0 (any), pT1-4 N1 M0, Resectable M1	Clear cell
RAMPART, (NCT03288532) [30]	Prospective, multicenter, double-blinded, placebo controlled	Durvalumab, Durvalumab + tremelimumab	1750	Leibovich Score 3-11	Any
Neoadjuvant Trials
Merck Sharp; Dohme Corp; (NCT02212730) [31]	Prospective, open label, parallel assignment	Pembrolizumab	36	cT1b+ NX-0 M0	Any
Bristol-Myers Squibb; (NCT02575222) [32]	Prospective, open label	Nivolumab	30	cT2a-T4 NX-1 M0, cT1-4 N1 M0	Clear cell
NCI (NCT02595918) [33]	Prospective, open label	Nivolumab	29	Stage I-III	Clear cell
Case Comprehensive Cancer Center; (NCT02762006) [34]	Prospective, open label	Durvalumab, Tremelimumab	45	cT2b-4 NX-0 M0; cT1-4 N1, M0	Any
PROSPER, (NCT03055013) [35]	Randomized, double-blind, placebo controlled	Nivolumab	766	cT2 NX M0, cT1-4 N1 M0	Any
Roswell Park Cancer Institute (NCT02170389) [31]	Prospective, open label	RCC/CD40L RNA-Transfected Autologous Vaccine	4	pT1, NX-0, M0	Any